|
KCTD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.8500999621196E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.139699994963E-08 |
| Normal-vs-Stage2 |
1.224660E-03 |
| Normal-vs-Stage3 |
1.41599999503583E-08 |
| Normal-vs-Stage4 |
3.86690000020451E-07 |
| Stage1-vs-Stage2 |
3.009400E-01 |
| Stage1-vs-Stage3 |
2.186400E-01 |
| Stage1-vs-Stage4 |
2.423800E-01 |
| Stage2-vs-Stage3 |
8.295700E-02 |
| Stage2-vs-Stage4 |
9.014300E-02 |
| Stage3-vs-Stage4 |
8.330000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.83240003568142E-10 |
| Normal-vs-AfricanAmerican |
3.998200E-02 |
| Normal-vs-Asian |
1.50343999999469E-05 |
| Caucasian-vs-AfricanAmerican |
4.847800E-02 |
| Caucasian-vs-Asian |
6.970200E-01 |
| AfricanAmerican-vs-Asian |
1.208020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.30619999985748E-07 |
| Normal-vs-Female |
3.61990004638102E-09 |
| Male-vs-Female |
8.131600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.28139999949961E-07 |
| Normal-vs-Age(41-60Yrs) |
1.1989000014978E-08 |
| Normal-vs-Age(61-80Yrs) |
3.00720000012689E-07 |
| Normal-vs-Age(81-100Yrs) |
4.540100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.973000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.996200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.939800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.353200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.247800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.469800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.561200E-03 |
| Classical-VS-Follicular |
3.564300E-02 |
| Classical-VS-Other |
2.920200E-01 |
| Classical-VS-Normal |
2.4762999983885E-08 |
| Tall-VS-Follicular |
5.51850000000131E-05 |
| Tall-VS-Other |
9.614600E-01 |
| Tall-VS-Normal |
7.75009945108707E-10 |
| Follicular-VS-Other |
8.073900E-02 |
| Follicular-VS-Normal |
1.084680E-03 |
| Other-VS-Normal |
2.397200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.89680000489889E-08 |
| Normal-vs-N1 |
3.63400000003011E-06 |
| N0-vs-N1 |
4.967000E-01 |
|
|
